News

FORT WORTH, TEXAS (Sept. 28, 2022) – Vetoquinol USA announces the launch of Simplera™ (florfenicol, terbinafine, mometasone furoate) Otic Solution for Dogs. It is the most affordable, single-dose treatment for canine otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).¹

Simplera is FDA-approved as the first and only bioequivalent generic to Claro® (florfenicol, terbinafine, mometasone furoate) Otic Solution.

“Ear infections are some of the most common reasons pet owners seek veterinary care for their dogs,”² said Eric M. Alsup, DVM, General Manager, Vetoquinol USA. “Simplera is a leading-edge solution at an economical price, and it doesn’t rely on at-home treatment by clients. This gives veterinarians the flexibility to treat effectively and affordably — while maximizing practice profitability and removing client compliance from the treatment equation.”

Simplera is effective for up to 30 days, giving pets lasting relief in just one dose using a combination of three active substances:

• Florfenicol, an antibacterial
• Terbinafine, an antifungal
• Mometasone furoate, a steroidal anti-inflammatory

With Simplera, veterinarians are assured each antibacterial and antifungal works according to the indication. Each component was demonstrated to be compatible — and additive — in a study.³

Simplera is made in North America, and Vetoquinol offers the same 100% sastifaction guarantee available with its other quality generic medications like Vetprofen® (carprofen) and Imoxi™(imidacloprid + moxidectin) Topical Solution.

Simplera™ is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

IMPORTANT SAFETY INFORMATION:

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. WARNINGS: Not for use in humans. Keep this and all drugs out of reach of children. Do not use in cats. In case of accidental skin contact, wash area thoroughly with water. Avoid contact with eyes. Humans with known hypersensitivity to florfenicol, terbinafine hydrochloride or mometasone furoate should not handle this product. PRECAUTIONS: Do not administer orally. Do not use in dogs with known tympanic membrane perforation. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment. Use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs (see ANIMAL SAFETY on label). Use with caution in dogs with impaired hepatic function (see ANIMAL SAFETY on label). The safe use of Simplera in dogs used for breeding purposes, during pregnancy, or in lactating bitches has not been evaluated. For full prescribing information, visit www.vetoquinolusa.com/simplera-info.

About Vetoquinol USA

Headquartered in Fort Worth, Texas, Vetoquinol USA is owned by Vetoquinol S.A., an independent, family-owned French pharmaceutical company founded in 1933. Dedicated exclusively to animal health, Vetoquinol USA is focused on the development, production, and marketing of FDA, EPA, NASC, and AAFCO-regulated pharmaceutical, nutritional, and dermatological products for small and large animals.

1. Elanco Product Price List. Updated June 1, 2022.
2. HealthyPaws Pet Insurance & Foundation. (2019) Cost of Pet Health Care Report. Available at https://www.healthypawspetinsurance.com/content/costofcare/pet-care-cost.... Accessed Sept. 28, 2022.
3. Simplera™ (florfenicol, terbinafine, mometasone furoate) Otic Solution Prescribing Information. Vetoquinol USA, Inc.

© 2022 Vetoquinol USA, Inc. Vetoquinol, the Vetoquinol logo are registered trademarks of Vetoquinol, and SIMPLERA is a pending trademark of Vetoquinol. Claro® is a registered trademark of Elanco or its affiliates. SIM-22-00006